Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

BACKGROUND: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. OBJECTIVE: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow‐on randomised controlled trial (CLASSIC I...

Full description

Saved in:
Bibliographic Details
Main Authors: Sandborn, W J, Hanauer, S B, Rutgeerts, P, Fedorak, R N, Lukas, M, MacIntosh, D G, Panaccione, R, Wolf, D, Kent, J D, Bittle, B, Li, J, Pollack, P F
Format: Artigo
Language:Inglês
Published: BMJ Group 2007
Subjects:
Inflammatory Bowel Disease
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2701613/
https://ncbi.nlm.nih.gov/pubmed/17299059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2006.106781
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items